Iovance stock drops 24% after it halts cancer-drug trial

Iovance Biotherapeutics Inc.’s stock fell sharply on heavier-than-usual volume on Wednesday, after the cancer-therapy company said the U.S. Food and Drug Administration placed a clinical hold on its trial for the lung-cancer treatment IOV-LUN-202.

Previous post This Tesla bull expects another ‘volatile’ year for EV maker
Next post Spreads tighten on ‘Magnificent Seven’ corporate bonds as investors take profits